Dr. Rajesh Rengasamy is the First-Generation Entrepreneur and is a Founder and CEO of METABIX. Heading Chemistry Operations and responsible for the overall management, operations, business development and customer relationship.
He Graduated in Organic Chemistry (PhD) from the Gyeongsang National University, South Korea and with subsequent post-doctoral studies at University of South Alabama, USA (2 years) along with teaching assistance to undergraduate students, and he has a track record of 8 patents and several publications.
Bringing 18+ years of Industrial Experience over several years in USA, South Korea, China, and India in Drug Discovery, including both small molecule and targeted protein degradation (PROTAC).
His noted contributions have been the discovery of OBX02-011 (EGFR Inhibitor) and J2H-2002 (EGFR PROTAC) for the treatment of lung cancer that have reached various phases of clinical trials.
Also handled projects related to Custom Synthesis, Process Development, Speciality Chemicals, Organic Materials, Prodrugs, and Metabolites.
In 2022, he promoted METABIX with a vision to be a differentiating CRO in all areas of chemistry.
METABIX is a Contract Research, Process Development and Manufacturing Organization providing comprehensive drug discovery and contract research services in partnership with healthcare companies worldwide.
Copyright © 2022. METABIX. All Rights Reserved.
Thanks a bunch for filling that out. It means a lot to us, just like you do! We really appreciate you giving us a moment of your time today. Thanks for being you. Having trouble? Contact us